Another little nugget that is worthy of a market release, 4 days...

Another little nugget that is worthy of a market release, 4 days old now.
We are just not being updated with company events and milestones.
As a shareholder I would like to see a more proactive CEO keeping our local market informed..

GENE Presents Study at 2021 San Antonio Breast Cancer SymposiumMELBOURNE, Australia, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease confirms that the Company’s Director of Clinical Affairs & Medical Education, Erika Spaeth, PhD will be presenting at 2021 San Antonio Breast Cancer Symposium.

• New geneType Breast Cancer Test showed improved discrimination and calibration over traditional clinical models.
• Study included over 200,000 participants to validate the risk model with an expanded panel of 313 SNPs.
• Poster Presentation highlights the ongoing development of geneType Breast Cancer Risk Test.
• GeneType for Breast Cancer can identify risk in more than 85% of women. Note that only about 15% of women with breast cancer have a family member with history of this disease*.

GENE is pleased to announce the Company’s Director of Clinical Affairs & Medical Education, Erika Spaeth, PhD will be presenting data from a new study the Company has undertaken with an expanded panel of 313 SNPs as part GENE’s ongoing test development and improvement for its geneType Breast Cancer Test.
.
.
Ref: https://www.globenewswire.com/news-release/2021/12/10/2350002/0/en/GENE-Presents-Study-Involving-200-000-Participants-at-2021-San-Antonio-Breast-Cancer-Symposium.html

.